clinic
cours
copd
intermitt
interrupt
acut
exacerb
especi
winter
month
one
studi
patient
mean
exacerb
per
year
rang
prevent
attenu
sever
exacerb
import
goal
manag
stabl
copd
educ
patient
stop
smoke
pulmonari
rehabilit
nutrit
earli
medic
intervent
symptom
worsen
help
prevent
exacerb
valu
pneumococc
vaccin
copd
still
debat
influenza
chronic
obstruct
pulmonari
diseas
copd
major
medic
problem
usa
copd
fourth
main
caus
death
although
establish
risk
factor
includ
occup
exposur
hereditari
antitrypsin
defici
cigarett
smoke
import
risk
factor
smoker
howev
develop
clinic
import
chronic
airflow
obstruct
proport
small
known
underli
host
factor
may
play
part
yet
precis
agreement
definit
copd
american
thorac
societi
defin
copd
diseas
process
featur
progress
chronic
airflow
obstruct
due
chronic
bronchiti
emphysema
obstruct
airflow
may
partli
revers
patient
may
manifest
bronchial
hyperrespons
exclud
definit
asthma
may
also
caus
chronic
airflow
obstruct
may
difficult
distinguish
copd
case
although
definit
copd
well
describ
common
usag
emphasi
term
chronic
bronchiti
may
ideal
chronic
bronchiti
defin
clinic
hypersecret
mucu
occur
mainli
larg
airway
site
progress
chronic
airflow
obstruct
suggest
definit
copd
emphasis
central
pathogen
role
inflammatori
process
progress
lead
obstruct
caus
fibrosi
distort
termin
airway
loss
alveolar
attach
tether
small
airway
hypersecret
mucu
contract
smooth
muscl
stabl
copd
patient
either
symptomfre
symptom
without
substanti
fluctuat
manag
aim
improv
qualiti
life
reliev
symptom
prevent
acut
exacerb
slow
progress
deterior
lung
function
acut
exacerb
underli
copd
common
caus
respiratori
deterior
develop
made
prevent
measur
admiss
hospit
acut
exacerb
expect
remain
common
sever
expert
consensu
guidelin
publish
defin
appropri
manag
copd
patient
consensu
guidelin
gener
agre
acknowledg
lack
larg
wellcontrol
clinic
studi
especi
studi
focus
manag
acut
exacerb
consequ
mani
potenti
controversi
exist
detail
manag
patient
acut
exacerb
although
studi
mani
fundament
aspect
manag
still
need
result
control
clinic
trial
suffici
emphasis
import
care
clinic
assess
supplement
oxygen
inhal
bronchodil
partial
improv
airway
obstruct
corticosteroid
decreas
likelihood
treatment
failur
speed
recoveri
antibiot
especi
sever
patient
noninvas
positivepressur
ventil
treatment
acut
ventilatori
failur
select
patient
pneumococc
vaccin
recommend
wide
use
decreas
frequenc
exacerb
convinc
data
support
chronic
intermitt
use
prophylact
antibiot
prevent
exacerb
chemoprophylaxi
amantadin
howev
consid
unvaccin
patient
period
high
risk
contract
influenza
infect
addit
strategi
prevent
exacerb
promis
present
trial
suggest
inhal
fluticason
may
role
longterm
treatment
copd
futur
studi
need
confirm
find
patient
exacerb
moder
sever
exacerb
time
placebo
time
inhal
fluticason
anoth
approach
use
immunostimul
bacteri
extract
bv
patient
stabl
copd
treat
bacteri
extract
frequenc
exacerbaton
placebo
requir
less
half
mani
hospit
day
trial
risk
admit
hospit
respiratori
problem
lower
group
bv
group
placebo
alter
mucu
product
also
use
tri
prevent
attenu
exacerb
trial
show
oncedaili
treatment
carbocystein
lysin
salt
significantli
decreas
frequenc
exacerb
carbocystein
thought
alter
mucu
product
stimul
sialyltransferas
activ
mucussecret
cell
although
dropout
rate
patient
notabl
analysi
intent
treat
show
treat
patient
free
exacerb
trial
compar
receiv
placebo
final
antioxid
nacetylcystein
may
also
prophylact
valu
decreas
frequenc
exacerb
exacerb
typic
includ
increas
cough
chang
volum
tenac
purul
sputum
increas
breathless
wheez
chest
tight
case
howev
cough
may
ineffect
sever
airway
obstruct
increas
sputum
product
appar
initi
assess
copd
patient
respiratori
deterior
clinician
look
evid
comorbid
disord
caus
contribut
respiratori
deterioraton
review
medic
sed
antagonist
final
acut
exacerb
copd
one
mani
caus
coughphlegm
syndrom
other
includ
postnasaldrip
syndrom
sinus
asthma
gastrooesophagealreflux
diseas
therefor
increas
cough
sputum
product
alon
patient
copd
may
indic
exacerb
histori
physic
assess
arteri
blood
gase
use
assess
sever
exacerb
judg
whether
patient
requir
admiss
hospit
physic
assess
particular
attent
paid
chang
mental
statu
use
accessori
muscl
respir
paradox
abdomin
breath
sinc
find
suggest
respiratori
failur
arteri
blood
gase
also
import
assess
tool
exact
valu
arteri
partial
pressur
oxygen
po
carbon
dioxid
pco
defin
acut
respiratori
failur
sinc
patient
copd
variou
baselin
valu
instead
chang
must
interpret
rel
baselin
valu
conjunct
symptom
gener
howev
arteri
po
less
kpa
pco
kpa
accompani
acut
acuteonchron
respiratori
acidosi
show
acut
respiratori
failur
clear
indic
admisson
hospit
absenc
acut
respiratori
failur
admiss
hospit
judg
abil
manag
daili
activ
mdimet
dose
inhal
peepposit
end
expiratori
pressur
recommend
weak
recommend
moder
recommend
strong
recommend
rrandomis
dbdoubleblind
pcplacebocontrol
gradat
base
perceiv
strength
best
evid
expert
consensu
patient
hospit
home
speed
worsen
symptom
ga
exchang
abnorm
respons
initi
therapi
patient
home
set
access
followup
sever
patient
baselin
airway
obstruct
unlik
assess
asthmat
role
spirometri
peakflow
measur
assess
need
emerg
admiss
hospit
establish
studi
found
poor
correl
spirometr
valu
alon
success
discharg
emerg
room
potenti
applic
spirometr
measur
acut
set
import
issu
lack
specif
criteria
admiss
undoubtedli
contribut
fact
least
copd
patient
discharg
emerg
depart
ultim
requir
admiss
hospit
goal
admiss
hospit
reliev
airway
obstruct
correct
hypoxaemia
address
comorbid
disord
eg
congest
heart
failur
pneumonia
may
also
contribut
respiratori
deterior
tabl
patient
exacerb
gener
medic
readi
discharg
clinic
stabl
parenter
therapi
h
requir
inhal
bronchodil
everi
h
stabl
arteri
blood
gase
h
abl
walk
least
short
distanc
followup
arrang
one
expert
consensu
guidelin
recommend
routin
follow
peak
expiratori
flow
twice
daili
patient
stay
hospit
assess
progress
howev
clinic
valu
approach
establish
guidelin
specif
recommend
practic
antibiot
therapi
although
noninfecti
caus
exacerb
may
import
eg
pollut
inhal
irrit
major
precipit
exacerb
copd
acut
airway
infect
infect
consequ
inflammatori
respons
host
lead
increas
airway
obstruct
least
third
exacerb
may
caus
viral
infect
one
studi
patient
rhinovirus
influenza
viru
parainfluenza
viru
coronaviru
significantli
associ
acut
exacerb
copd
patient
seem
increas
suscept
virus
viral
infect
seriou
consequ
copd
patient
role
bacteria
precipit
exacerb
controversi
bacteria
may
primari
role
develop
exacerb
repres
secondari
superinfect
initi
viral
process
controversi
stem
partli
presenc
variou
bacteri
speci
airway
patient
even
copd
stabl
role
bacteri
infect
suggest
abund
neutrophil
sputum
fact
bacteria
often
recover
acut
exacerb
compar
stabl
copd
support
role
major
bacteri
organ
associ
exacerb
haemophili
influenza
streptococcu
pneumonia
moraxella
branhamella
catarrhali
mycoplasma
pneumonia
chlamydia
pneumonia
may
play
part
evid
also
suggest
acut
exacerb
patient
baselin
forc
expiratori
volum
fev
less
predict
gramneg
bacteria
especi
enterobacteriacea
pseudomona
spp
play
import
part
acut
exacerb
effect
antibiot
also
suggest
aetiolog
role
bacteria
exacerb
patient
metaanalysi
nine
studi
show
small
overal
benefit
antibiot
treatment
copd
exacerb
largest
studi
includ
exacerb
outpati
compar
placebo
rate
symptom
resolut
improv
peak
expiratori
flow
exacerb
slightli
significantli
faster
patient
treat
cotrimoxazol
amoxicillin
doxycyclin
exampl
patient
receiv
antibiot
mean
peak
expiratori
flow
increas
lmin
lmin
day
antibiot
use
exacerb
improv
peak
expiratori
flow
seen
day
importantli
treatment
failur
defin
respiratori
deterior
nearli
twice
like
placebo
group
benefit
antibiot
evid
patient
symptom
dyspnoea
increas
sputum
volum
sputum
purul
trend
favour
antibiot
corticosteroid
use
although
viral
infect
probabl
account
mani
exacerb
copd
bacteri
infect
aetiolog
role
exacerb
patient
mani
clinician
use
antibiot
treat
exacerb
especi
patient
least
two
increas
dyspnoea
increas
sputum
volum
sputum
purul
patient
admit
hospit
acut
exacerb
copd
rational
antibiot
treatment
antibiot
help
patient
worst
symptom
antibiot
substanti
decreas
rate
treatment
failur
patient
littl
margin
respiratori
deterior
slightli
increaas
rate
recoveri
risk
sideeffect
antibiot
low
aetiolog
role
bacteria
individu
case
exclud
inexpens
antibiot
amoxicillin
cotrimoxazol
doxycyclin
gener
select
treatment
outpati
resist
organ
suspect
sever
patient
clinic
condit
put
highrisk
treatment
failur
second
third
gener
cephalosporin
fluoroquinolon
newer
macrolid
broadspectrum
penicillin
may
prefer
studi
need
select
patient
benefit
antibiot
show
optimum
antibiot
choic
given
local
chang
resist
pattern
establish
durat
antibiot
therapi
test
hypothesi
recurr
infect
role
progress
copd
acut
inflammatori
respons
infect
airway
stimul
mucu
hypersecret
airwaywal
oedema
smoothmuscl
contract
abund
neutrophil
sputum
suggest
primari
secondari
bacteri
infect
one
studi
shown
sputum
sampl
acut
exacerb
typic
greater
increas
eosinophil
neutrophil
bronchial
biopdi
show
substanti
airway
eosinophilia
small
increas
neutrophil
activ
lymphocyt
although
alway
question
well
asthmat
exclud
seminar
lancet
vol
august
seminar
studi
eosinophil
inflamm
seem
differ
seen
asthmat
sinc
express
interleukin
seen
exacerb
copd
theoret
corticosteroid
could
decreas
airway
inflamm
copd
one
studi
show
sever
obstruct
patient
treat
intraven
methylprednisolon
rapid
improv
fev
first
h
stay
hospit
patient
given
corticosteroid
absolut
differ
group
small
increas
fev
ml
methylprednisolon
group
ml
placebo
group
studi
show
howev
patient
receiv
methylprednisolon
improv
fev
h
three
patient
placebo
similar
improv
anoth
studi
outpati
assess
effect
corticosteroid
exacerb
copd
found
corticosteroid
slightli
increas
rate
improv
oxygen
spirometri
decreas
treatment
failur
rate
patient
treat
placebo
eight
improv
symptom
requir
admiss
hospit
patient
treat
prednisolon
none
treatment
failur
differ
studi
patient
suggest
corticosteroid
significantli
decreas
rate
relaps
first
h
discharg
emerg
depart
final
data
system
corticosteroid
copd
exacerb
clinic
trial
support
use
corticosteroid
patient
admit
hospit
acut
exacerb
copd
trial
patient
treat
system
corticosteroid
fewer
treatment
failur
better
spirometri
shorter
hospit
stay
base
evid
patient
admit
hospit
copd
exacerb
commonli
receiv
system
corticosteroid
rational
although
favour
effect
corticosteroid
modest
even
small
improv
benefici
patient
sever
airway
obstruct
toler
respiratori
deterior
addit
studi
need
find
optimum
dose
durat
corticosteroid
therapi
acut
exacerb
importantli
resolut
acut
exacerb
corticosteroid
day
taken
indic
chronic
systemiccorticosteroid
therapi
obstruct
airflow
result
increas
respiratori
work
hyperinfl
place
respiratori
muscl
mechan
disadvantag
impair
ventilationperfus
match
caus
hypoxaemia
therefor
relief
airflow
obstruct
prevent
correct
respiratori
failur
major
goal
treatment
acut
exacerb
relief
bronchoconstrict
rapid
mean
improv
airway
resist
improv
airflow
may
help
make
cough
effect
clear
secret
unfortun
bronchoconstrict
gener
major
caus
airway
obstruct
exacerb
copd
therefor
immedi
effect
bronchodil
often
slight
small
improv
airfow
may
howev
benefit
patient
sever
airflow
obstruct
therefor
rapidli
act
agonist
deliv
aerosol
mainstay
initi
treatment
one
typic
studi
inhal
orciprenalin
increas
fev
l
l
min
evid
suggest
metereddos
inhal
spacer
effect
wet
nebulis
deliveri
agonist
ipratropium
bromid
anticholinerg
deliv
inhal
use
treat
acut
exacerb
singl
agent
effect
ipratropium
spirometri
least
equal
slight
effect
agonist
possibl
less
risk
decreas
blood
oxygen
patient
exacerb
copd
inhal
ipratropium
small
signific
increas
kpa
arteri
po
within
min
contrast
inhal
metaproterenol
transient
decreas
kpa
arteri
po
decreas
arteri
po
agonist
attribut
transient
worsen
ventilationperfus
match
vasodil
pulmonari
vasculatur
increas
cardiac
output
sinc
rate
onset
bronchodil
slow
ipratropium
peak
effect
min
mani
physician
prefer
agonist
firstlin
bronchodil
acut
exacerb
practic
agonist
ipratropium
frequent
combin
treat
exacerb
especi
patient
respond
poorli
therapi
extrapol
studi
patient
stabl
copd
support
combin
therapi
least
one
studi
acut
exacerb
show
benefit
combin
agent
role
bronchodil
theophyllin
intraven
aminophyllin
diminish
toxic
effect
littl
proof
efficaci
combin
bronchodil
one
studi
show
aminophyllin
ad
benefit
standard
treatment
acut
exacerb
copd
anoth
show
nonsignific
trend
favour
aminophyllin
drug
use
mainli
inhal
agent
given
airway
open
inflammatori
respons
promot
mucu
hypersecret
bronchoconstrict
decreas
bronchodil
antibiot
cortiosteroid
help
reliev
airway
obstruct
decreas
tracheobronchi
secret
addit
agonist
may
stimul
mucociliari
clearanc
besid
pharmacolog
measur
cigarett
smoke
stop
irrit
effect
smoke
may
stimul
mucu
secret
promot
airway
inflamm
impair
mucociliari
clearanc
teach
huff
cough
may
help
patient
clear
secret
measur
improv
clearanc
mucu
exacerb
eg
expector
mucolyt
nacetylcystein
iodid
guaifenesin
dnase
limit
proven
valu
unless
ml
sputum
produc
per
day
mucu
plug
lobar
atelectasi
chest
physiotherapi
proven
valu
exacerb
nasotrach
suction
use
help
patient
clear
secret
techniqu
seriou
risk
believ
safer
altern
use
similarli
bland
aerosol
therapi
system
hydrat
excess
euvolaemia
proven
role
treatment
copd
exacerb
hypoxaemia
caus
mainli
worsen
ventilationperfus
match
airway
obstruct
becom
sever
durat
lengthen
respiratori
muscl
may
unabl
sustain
breath
alveolar
hypoventil
contribut
hypoxaemia
hypercarbia
respiratori
acidosi
hypoxaemia
respiratori
acidosi
promot
pulmonari
vasoconstrict
turn
caus
high
pulmonaryarteri
pressur
impos
ad
load
right
ventricl
heart
rightventricular
failur
complic
exacerb
copd
supplement
oxygen
diuret
digitali
improv
function
sever
hypoxaemia
hypercarbia
respiratori
acidosi
may
also
compromis
leftventricular
function
precipit
arrhythmia
impair
respiratori
muscl
depress
mental
statu
correct
hypoxaemia
achiev
arteri
oxygen
tension
least
kpa
immedi
prioriti
manag
patient
admit
hospit
acut
exacerb
copd
specif
recommend
stepwis
control
correct
hypoxaemia
made
guidelin
mani
case
lowflow
oxygen
administ
nasal
prong
lmin
venturityp
facial
mask
suffici
administr
oxygen
care
control
arteri
blood
gase
serial
monitor
patient
arteri
pco
may
increas
acut
respiratori
acidosi
occur
patient
develop
arteri
ph
less
supplement
oxygen
deliv
significantli
poorer
outlook
mechan
underli
acut
increas
arteri
pco
occur
patient
clear
emphasi
previous
place
incorrectli
supplement
oxygen
therapi
caus
hypercapnia
depress
hypox
drive
breath
patient
copd
evid
suggest
minut
ventil
drive
breath
decreas
supplement
oxygen
rise
arteri
pco
administr
supplement
oxygen
probabl
due
haldan
effect
worsen
ventilationperfus
match
neuromuscular
function
may
unabl
meet
sustain
increas
work
breath
impos
increas
obstruct
airflow
impair
neuromuscular
function
depress
conscious
fatigu
weak
respiratori
muscl
contribut
acut
ventilatori
failur
exacerb
copd
therefor
correct
factor
impair
respiratori
neuromuscular
function
import
electrolyt
disturb
paincaus
splint
abdomin
distens
ascit
poor
nutrit
sedat
drug
contraind
unless
patient
receiv
assist
ventil
use
respiratorymuscl
stimul
doxapram
increas
alveolar
ventil
acut
ventilatori
failur
may
benefici
one
studi
half
mani
patient
treat
doxapram
increas
pco
first
h
admiss
hospit
studi
shown
doxapram
decreas
need
assist
ventil
use
medic
treat
patient
acut
ventilatori
failur
wide
adopt
despit
maximum
medic
therapi
patient
exacerb
copd
sever
progress
acut
respiratori
acidosi
sever
hypoxaemia
despit
supplement
oxygen
assist
ventil
provid
shortterm
support
airway
obstruct
treat
evid
indic
noninvas
positivepressur
assist
ventil
use
sever
ill
patient
requir
immedi
endotrach
intub
mechan
ventil
potenti
complic
barotrauma
infect
avoid
best
time
start
noninvas
mechan
ventil
establish
earli
intervent
respiratori
rate
breath
per
min
ph
less
suggest
success
noninvas
positivepressur
assist
ventil
improv
respiratori
rate
ph
within
h
posit
pressur
via
tightfit
facial
nasal
mask
lessen
work
breath
may
allow
recoveri
fatigu
respiratori
muscl
interestingli
even
brief
period
hday
noninvas
support
seem
decreas
risk
eventu
need
intub
techniqu
recommend
toler
cooper
patient
sedat
haemodynam
stabl
abl
protect
airway
clear
secret
importantli
care
intensivecar
support
staff
familiar
noninvas
support
techniqu
probabl
becom
increasingli
popular
shortterm
intervent
select
patient
decis
intub
initi
mechan
ventil
complex
patient
baselin
qualiti
life
import
consider
panel
notabl
absolut
valu
arteri
pco
alon
use
indic
need
intub
sinc
mani
patient
sever
copd
may
baselin
compens
respiratori
acidosi
requir
assist
ventil
arteri
pco
must
assess
relat
arteri
ph
patient
requir
intub
mechan
ventil
exacerb
support
positivepressur
ventil
assistcontrol
intermittentmandatori
pressuresupport
ventilatori
method
pressuresupport
ventil
may
comfort
patient
outcom
shown
differ
two
method
major
complic
invas
positivepressur
ventil
barotrauma
pneumonia
local
complic
endotrach
tube
risk
barotrauma
decreas
keep
autoposit
endexpiratori
pressur
minimum
gener
manag
practis
follow
generalmanag
plan
inpati
treatment
acut
exacerb
copd
assess
begin
clinic
assess
measur
arteri
blood
gase
evid
respiratori
failur
need
assist
ventil
seminar
lancet
vol
august
gener
guidelin
endotrah
intub
acut
exacerb
copd
persist
hypoxaemia
failur
reach
arteri
po
mm
hg
satur
despit
maximum
therapi
includ
supplement
oxygen
worsen
acut
respiratori
acidosi
despit
maximum
therapi
sign
progress
respiratorymuscl
fatigu
despit
maximum
therapi
deterior
mental
statu
inabl
protect
airway
inabl
clear
copiou
secret
identifi
comorbid
ill
pneumonia
medic
could
contribut
respiratori
deterior
variou
treatment
start
control
lowflow
supplement
oxygen
deliv
achiev
maintain
arteri
po
least
kpa
deliveri
oxygen
nasal
prong
gener
prefer
mask
deliveri
prong
comfort
patient
like
leav
place
arteri
blood
gase
measur
serial
patient
supplement
oxygen
ensur
among
minor
develop
respiratori
acidosi
upon
deliveri
oxygen
administ
broadspectrum
antibiot
patient
admit
hospit
sever
airflow
obstruct
high
risk
treatment
failur
gener
select
secondgener
cephalosporin
fluoroquinolon
secondgener
macrolid
bronchospasm
treat
mucociliari
clearanc
possibl
improv
inhal
agonist
given
metereddos
inhal
spacer
direct
supervis
patient
sever
rapidli
progress
deterior
slight
respons
agonist
ipratropium
inhal
everi
h
ad
patient
start
intraven
methylprednisolon
chang
prednisolon
day
clear
improv
seen
help
mobilis
secret
patient
encourag
cough
sit
upright
chair
earli
ambul
encourag
chest
physiotherapi
done
routin
sinc
evid
insuffici
show
valu
acut
exacerb
throughout
treatment
patient
undergo
frequent
clinic
assess
arteri
blood
gase
oximetri
monitor
assess
respons
therapi
patient
sever
worsen
symptom
respiratori
acidosi
despit
therapi
hypoxaemia
supplement
oxygen
assist
ventil
use
panel
select
patient
noninvas
ventil
prefer
gener
approach
acut
exacerb
copd
must
acknowledg
lack
larg
doubleblind
placebocontrol
clinic
trial
address
fundament
question
manag
comprehens
wide
accept
evidencedbas
guidelin
manag
yet
exist
expert
consensu
guidelin
howev
agre
mani
issu
